ClinicalTrials.gg
Enrolling by invitationNCT07046143Updated Dec 22, 2025

Study on the Efficacy of Non-invasive Spinal Cord Electrical Stimulation in Neuropathic Pain

An interventional study of tSCS in Neuropathic Pain, sponsored by Nanchang University Affiliated Rehabilitation Hospital. Enrolling by invitation at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-12-22.

Sponsored by Nanchang University Affiliated Rehabilitation Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as enrolling by invitation.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
62
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 41 studies in Neuralgia with a site in China — 17 open to participants now, 17 under way, 1 of them phase 3. Neuralgia · China.

Planned enrollment
26th of 31
62 · median 147
Started
2025
with 6 others
No phase
12 of 41
5 open now
Primary completion
2026-06
later than 7 of 16 live
Registered
32nd of 41
by date

Among the 41 studies in Neuralgia with a site in China, this one is the 26th largest by planned enrollment of the 31 interventional ones that give a count, is one of 7 that started in 2025, is one of 12 with no phase, reaches primary completion later than 7 of the 16 other live ones, and was the 32nd registered.

Neuralgia

1,103 studies on the registry are indexed under Neuralgia; 243 are open to participants now.

Browse Neuralgia studies →

Open to participants now

17 of the 41 studies in Neuralgia with a site in China are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 155 Neuralgia studies recruiting now, 79 (51%) set no upper age limit and 44 (28%) stop at 75 or younger; 8 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies in Neuralgia with a site in China, or all of them as a file.
02

Study summary

This study is a randomized, double-blind, controlled clinical trial designed to evaluate the impact of non-invasive spinal cord electrical stimulation (tSCS) on the outcome of patients with neuropathic pain.Subjects will be randomized into a test group (treated with tSCS) and a control group (receiving sham stimulation).The intervention period was during the patient's hospitalization, with a follow-up period of 3 months.Patients' pain and quality of life will be assessed at baseline, at the end of the intervention, and during the follow-up period to compare the difference in efficacy between the two groups.

Read the detailed description

The study subjects were patients with low back pain caused by neuropathic pain patients, who were assessed and screened by professionally trained medical personnel according to the inclusion and exclusion criteria, and those who met the enrollment criteria signed an informed consent form after they gave their informed consent and were formally included in the study. A computerized randomization system was applied to randomly divide them into a test group and a control group.Both groups were operated with non-invasive spinal cord stimulation devices manufactured by the same company, with the test group receiving real and effective non-invasive spinal cord electrical stimulation (Device A), while the control group received placebo stimulation (Device B). Throughout the double-blind intervention, neither the subjects nor the assesseors who operated the devices were aware of the difference between the two devices (Device A and Device B) and were completely blinded.

For the subjects randomized to receive noninvasive spinal cord electrical stimulation, the unblinded researchers carried out the study according to the following research steps: ① Before the treatment, the patient's skin was wiped with 75% alcohol, and the patient was asked to take a prone or sitting position, The anode is placed above the anterior superior iliac spine on the affected side, while the cathode covers the paravertebral region of the lumbosacral enlargement corresponding to the painful dermatome.② The stimulation frequency was adjusted to 10,000Hz, the treatment frequency was 30Hz, the pulse width was 1ms, the waveform was square wave, and the duration of single treatment was 20min. ③ The test group's stimulation intensity was set at the patient's tolerable threshold. The placebo control group's initial stimulation intensity was set at the sensory threshold, maintained for 30 seconds, and then gradually reduced to zero over the remaining duration.④ The equipment was sterilized by wiping with 75% alcohol after the treatment.Subjects randomized to receive sham stimulation operated according to the above study steps, and the device output interface adjustment parameters were all consistent. Both the test group and the control group received non-invasive spinal cord electrical stimulation during hospitalization, twice daily for 20 minutes each session. During the study period, subjects in both groups received the same other conventional rehabilitation treatments.

The basic information of the patients was recorded before treatment, including gender, age, etiology, and duration of the disease.The McGill Pain Questionnaire (MPQ), Visual Analog Scale (VAS), Oswestry Dysfunction Index Questionnaire (ODI), EEG data during tSCS stimulation, Quality of Life Scale (SF-36), and Patient General ImpressionImprovement Scale (CGI-1), Pittsburgh Sleep Quality Index (PSQI), Self-Assessment Scale for Anxiety (SAS), Self-Assessment Scale for Depression (SDS).

03

Conditions studied

  • Neuropathic Pain

Keywords

  • Transcutaneous spinal cord electrical stimulation
  • Neuropathic Pain
  • lumbago
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-80 years old;
  • Meet the diagnostic criteria for neuropathic pain
  • Chronic low back pain due to neuropathic pain, with or without leg pain;
  • The skin at the site of irritation is intact;
  • The patient's vital signs are stable.

Exclusion criteria

Exclusion Criteria:

  • Pain is mainly caused by non-neuropathic factors, such as acute inflammation and trauma;
  • Those with severe mental illness affecting the study assessment, those with severe cognitive impairment unable to communicate normally or with very poor compliance;
  • Accompanied by severe cardiac, hepatic, renal and other vital organ insufficiency;
  • Recently received other related treatments that may affect the impact of neuropathic pain.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
62 participants (estimated)

Study arms

  • Experimental
    test group

    The experimental group received noninvasive spinal cord electrical stimulation treatment

    Device: tSCS

  • No intervention
    control group

    The placebo control group's initial stimulation intensity was set at the sensory threshold, maintained for 30 seconds, and then gradually reduced to zero over the remaining duration.

Interventions

  • DevicetSCS

    The test group received non-invasive spinal cord electrical stimulation therapy during hospitalization. Patients were positioned prone or seated, with the anode placed above the iliac crest on the affected side and the cathode covering the paravertebral region of the lumbosacral enlargement corresponding to the painful dermatome. The stimulation frequency was adjusted to 10,000 Hz, with a treatment frequency of 30 Hz and a pulse width of 1 millisecond. The waveform was square, with each treatment session lasting 20 minutes. Stimulation intensity was set to the patient's tolerable threshold. Sessions were administered twice daily, each lasting 20 minutes.

06

What researchers measure

Primary outcomes

  1. McGill Pain Questionnaire

    McGill Pain Questionnaire (MPQ): (1) The questionnaire contains two main categories, the Pain Rating Index (PRI) and the Pain Intensity (PI). (2) The PRI section consists of 20 subcategories totaling 78 descriptive words, and patients are asked to mark one word from each category that best indicates their pain (no suitable may be left unchecked), and these words indicate the different components of pain. categories 1-10 are sensory, 11-15 are affective, 16 are evaluative, and 17-20 are other.Scores are 0-78, with 0 being no pain and 78 being severe pain. (3) The PPI can be used to assess the intensity of generalized pain on a scale of 0-5, with the higher the score, the more pronounced the pain.

    Time frame: Study pre-intervention and post-intervention weeks one and two

  2. The Oswestry Dysfunction Index Questionnaire

    The Oswestry Dability Index is a 10-question questionnaire consisting of 10 questions on pain intensity, self-care, lifting, walking, sitting, standing, disturbed sleep, sexuality, social life, and travel, with 6 options for each question and a maximum score of 5 for each question.The maximum score for each question is 5 points, 0 points for the first option and 5 points for the last option in that order. If all 10 questions are answered, the score is: actual score/50 (highest possible score) x 100%, and if one question is not answered, the score is: actual score/45 (highest possible score) x 100%, with higher scores indicating more severe dysfunction.

    Time frame: Study pre-intervention and post-intervention weeks one and two

  3. Visual Analog Scale

    Visual analog scoring method.A 10 cm horizontal line was drawn on the paper, with 0 mm at one end of the line, indicating "no pain at all", and 10 mm at the other end, indicating "extreme pain"; the pain level increased from 0 mm to 10 mm, and the higher the score, the more intense the pain.The higher the score, the more intense the pain.

    Time frame: Study pre-intervention and post-intervention weeks one and two

  4. EEG

    The recording parameters are as follows: recording bandwidth(dc-1000hz),sampling rate (1000hz). The main measures of eeg are as follows and focued on 0.1- 40hz thus include delta, theta, alpha, beta and gamma band: qualitative waveform, power spectral density, fuctional connectivity, graph theory measurs. However, since biomarkers of pain is just one of the study objectives, we can not determine all measures that might be used in the future.

    Time frame: Study pre-intervention and post-intervention weeks one and two

Secondary outcomes

  1. Quality of Life Scale

    for assessing the overall quality of life of patients

    Time frame: Pre-treatment and first week, second week, 3 months, 6 months, 1 year post-treatment

  2. Patient General Impression of Improvement Scale

    to assess patient self-perceived improvement in pain

    Time frame: Pre-treatment and first week, second week, 3 months, 6 months, 1 year post-treatment

  3. Pittsburgh Sleep Quality Index

    assesses the quality of a patient's sleep

    Time frame: Pre-treatment and first week, second week, 3 months, 6 months, 1 year post-treatment

  4. Self-assessment scale for anxiety

    assessment of the patient's psychological status. Anxiety scale: normal (\<50 points); mild anxiety (50-60 points); moderate anxiety (61-70 points); severe anxiety (\>70 points).

    Time frame: Pre-treatment and first week, second week, 3 months, 6 months, 1 year post-treatment

  5. Self-assessment scale for depression

    Depression scale: mild depression (53-62 points); severe depression (63-72 points); severe depression (\>72 points).

    Time frame: Pre-treatment and first week, second week, 3 months, 6 months, 1 year post-treatment

07

Study locations

1 site
  • NanChang
    Nanchang, Jiangxi 330003, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Jun 2026, 11 months after the start.

Of 249 non-industry interventional studies with no phase under Neuralgia, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 41. This study's planned 11 months is below that.

Counting every sponsor, half of 267 studies reached it within 24 months; a quarter within 10 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
May 31, 2025
First posted
Jul 1, 2025
StartActual
Jun 25, 2025
Primary completionEst.
Jun 15, 2026
CompletionEst.
Jul 15, 2026
Last update
Dec 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07046143
Lead sponsor
Nanchang University Affiliated Rehabilitation Hospital
Responsible party
Wentao Zeng (Prinicipal Investigator, Nanchang University Affiliated Rehabilitation Hospital) — Principal investigator
First posted
Jul 1, 2025
Start date
Jun 25, 2025
Primary completion
Jun 15, 2026 (estimated)
Completion
Jul 15, 2026 (estimated)
Last update
Dec 22, 2025

Study contacts

Ying Liang
study director · Affiliated Rehabilitation Hospital of Nanchang University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion